Bioserve
Bioserve is a Hyderabad-based molecular biology services company and India subsidiary of REPROCELL Inc. offering custom oligonucleotide synthesis, NGS/Sanger sequencing, the PreciONC clinical oncology diagnostics suite, and stem cell products to Indian pharmaceutical companies, academic institutions, and healthcare providers.
- Company typePrivate
- Founded1994
- HeadquartersHyderabad, India
- Headcount51–100
- GTM typeB2B
- OfferingServices
What Bioserve does
Bioserve Biotechnologies (India) Pvt. Ltd. is a Hyderabad-based molecular biology services and products company operating as the wholly-owned India subsidiary of REPROCELL Inc. (Tokyo Stock Exchange: 4978), Japan's first publicly listed iPSC company. Founded in 1994 and headquartered in Nacharam, Hyderabad, the company serves Indian pharmaceutical and biotechnology companies (Syngene, Lupin, Dr. Reddy's, Biological E, Aurobindo, Aurigene, Alembic, Zydus), academic and research institutions (IIT Madras, IIT Bombay, IARI), and healthcare providers (AIIMS). Bioserve's core capabilities span custom oligonucleotide synthesis (including proprietary Long Mer® oligos up to 150 bases and NGS Grade® oligos), the PreciONC clinical diagnostics suite (cancer panels covering 409 tumor suppressor/oncogenes with TMB/MSI testing, BRCA extended, hereditary cancers, lung RNA fusion, leukemia, and colorectal panels), molecular services (Sanger sequencing on ABI 3730 platforms, NGS on Illumina/PacBio/Oxford Nanopore, microbial ID and DNA barcoding), and stem cell products distributed from REPROCELL's portfolio (StemRNA™ reprogramming kits, iPSCs, MSCs, Alvetex 3D culture, ABLE Biott bioreactors, Qkine growth factors).
The company makes money through project-based and unit-based fees across five streams: oligonucleotide synthesis (one-time synthesis fees, 10-1000 nmole scale tiers), peptide synthesis (catalog and custom including GMP-grade APIs via HLB PEP), clinical diagnostics (precision oncology professional services), molecular services (sequencing and barcoding per-sample pricing), and stem cell product distribution (REPROCELL/Qkine/HLB PEP catalogs). Pricing is quote-based and not publicly disclosed; services are sold via direct sales, downloadable order forms, inside sales contacts (e.g., Oligo Synthesis, CRO, Sanger order forms), and event-driven lead generation at industry conferences. Bioserve holds ISO 9001:2015 and Clinical Establishment certifications, operates GMP procedures for peptide and iPSC manufacturing, and is currently expanding through new clinical product launches (NeoSight neoantigen detection, launched August 2025) and distribution partnerships.
Bioserve firmographics
Firmographics- Name
- Bioserve
- Legal name
- Bioserve Biotechnologies (India) Pvt. Ltd.
- Website
- https://bioserve.in
- Company type
- Private
- Founded year
- 1994
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Bioserve is a Hyderabad-based molecular biology services company and India subsidiary of REPROCELL Inc. offering custom oligonucleotide synthesis, NGS/Sanger sequencing, the PreciONC clinical oncology diagnostics suite, and stem cell products to Indian pharmaceutical companies, academic institutions, and healthcare providers.
- Ownership category
- akta.pro rank
Bioserve industry classification
Industry- Product category
- Genomics & Molecular Biology Services
- NAICS
- Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731), Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA) (HLAGAGAC)
- akta.pro secondary industries
- Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB), Transcriptomics & Gene Expression Profiling Services (HLAGANAE)
Keywords
Where Bioserve is headquartered
LocationHeadquarters
- HQ city
- Hyderabad
- HQ country
- India
- HQ region
- Asia
Offices1 record
Markets served
Bioserve business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales
Revenue model
- Oligonucleotide Synthesis Services: Custom DNA oligo synthesis services with various scales (10-1000 nmole), purification options, and modifications including dyes, quenchers, and labeled bases. Revenue generated from one-time synthesis fees with optional premium purification tiers.
- Peptide Synthesis Services: Custom peptide synthesis including catalog peptides (1000+), custom peptides (long-chain, modified, bulk-scale), and GMP-grade peptide APIs. Manufactured under GMP procedures with full traceability.
- Clinical Diagnostics Services: Precision oncology services including cancer panels (BRCA 1/2, Comprehensive Cancer Panel, Hereditary Cancers Panel), MSI testing, and biomarker testing for clinical diagnostics
- Molecular Services: Sanger sequencing (3-4 business days turnaround), Next-Generation Sequencing (DNA and RNA), microbial identification, and DNA barcoding services
- Stem Cell Products: Stem cell reagents, iPSCs, growth factors, cytokines, 3D cell culture products, and labware distributed through REPROCELL brand portfolio
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Oligo Synthesis - Scale-based pricing |
| Unit Pricing | Pay-as-you-go | Sanger Sequencing - Sample-based pricing |
| Unit Pricing | Pay-as-you-go | Qkine Growth Factors - Catalog products |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels9 records
Bioserve product offering
Product offeringCore offering
Bioserve is a molecular biology services and genomics company offering custom oligonucleotide synthesis (DNA oligos up to 150 bases), clinical diagnostics for oncology (BRCA, MSI, comprehensive cancer panels, lung RNA fusion panels), molecular services (Sanger sequencing, NGS, DNA barcoding, microbial identification, cell line authentication), neoantigen discovery for cancer immunotherapy, and stem cell research products including iPSCs, MSCs, growth factors, cytokines, and 3D cell culture systems. The company distributes REPROCELL group products, HLB PEP peptides, and Qkine growth factors to pharmaceutical, academic, and clinical customers in India.
Product overview
Bioserve is a comprehensive molecular biology services and products company offering oligonucleotide synthesis, clinical diagnostics, and stem cell research reagents. The core portfolio includes Oligosynthesis Services (custom DNA oligonucleotides including Long Mer DNA oligos up to 150 bases, Modified DNA oligos, NGS Grade oligos), the PreciONC Oncology clinical diagnostics suite (Integrated Tumor Panel+, MSI Testing, Lung RNA Fusion Panel, BRCA Extended Panel, Comprehensive Cancer Panel, Hereditary Cancers Panel, Colorectal Cancer Panel, Leukemia Panels), and Stem Cell Products (StemRNA reprogramming kits, iPSCs, MSCs, growth factors/cytokines from Qkine, 3D cell culture systems like Alvetex, bioreactors, and peptides from HLB PEP). The company also provides molecular services including Sanger Sequencing, Next-Generation Sequencing (Illumina, PacBio, Oxford Nanopore), DNA Barcoding, Microbial Identification, and Human Cell Line Authentication. Services are supported by ISO 9001:2015 certification and REPROCELL group partnership.
Differentiator
Problem solved
Functional benefit
Brands
- PreciONC: Precision oncology services including cancer genetic testing panels (BRCA, comprehensive cancer panel, inherited cancers panel, colorectal cancer panel, leukemia testing, MSI testing, lung RNA fusion panel)
- REPROCELL Group Products
- Long Mer
- NGS Grade
- StemRNA
Products and services
- Oligonucleotide Synthesis Services Custom DNA oligonucleotide synthesis services including Long Mer® DNA oligos (up to 150 bases), NGS Grade® oligos, modified DNA oligos with fluorescent labels and quenchers, and universal primers. Synthesized at scales from 10 to 1000 nmole with various purification options for pharmaceutical, biotech, and academic researchers.
- PreciONC Oncology Clinical Diagnostics Integrated molecular diagnostic suite for oncology covering hereditary risk assessment, differential diagnosis, prognosis, targeted treatment selection, therapy monitoring, and disease surveillance through multiple cancer panels.
- NeoSight Neoantigen Detection Service End-to-end neoantigen discovery platform combining Whole Exome Sequencing (WES), RNA Sequencing, and computational MHC-binding prediction algorithms to identify tumor-specific neoantigens for personalized cancer immunotherapy, with annotated VCF/TSV variant files, prioritized neoantigen lists, HLA typing, and TMB reports.
- Human Cell Line Authentication Service
- Sanger Sequencing Services
- Next-Generation Sequencing Services
- DNA Barcoding Services
- Microbial Identification Service
- StemRNA 3rd Gen Reprogramming Kit
- Induced Pluripotent Stem Cells (iPSCs)
- Qkine Growth Factors and Cytokines
- HLB PEP Peptide Solutions Peptide products including catalog peptides (>1000 hormones, neuropeptides, antibiotic peptides), custom peptide synthesis (long-chain, modified, bulk-scale), generic peptide APIs (Desmopressin, Leuprorelin, Ganirelix), and GMP-grade peptides from Korea's first MFDS-approved peptide facility.
- PreciONC Hereditary Cancers Panel
- PreciONC BRCA Extended Panel
- PreciONC MSI Testing
- PreciONC Lung RNA Fusion Panel
Quantifiable outcome
- 100+ completed projects
- +3 more outcomes
Companies that use Bioserve
Customer profileNamed customers13 records
Segments4 records
Ideal customer profiles4 records
Bioserve technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature7 records
Bioserve partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered strategic, core and minor.
- Histocell S.L.strategicJoint GMP certification achieved with Histocell for manufacturing clinical-grade iPSC master and working cell banks using StemRNA™ Clinical iPSCs. Spanish AEMPS (under EMA oversight) granted GMP certification.
- Durham UniversitystrategicREPROCELL Europe collaborated with Durham University researchers to develop iPSC-derived full-thickness human skin model. Breakthrough published in Cells journal (14(14):1044, 2025).
- HLB PEP Co., Ltd.coreExclusive distribution agreement for peptide products in Indian market. HLB PEP is Korea's first GMP-certified peptide CMO, providing catalog peptides, custom synthesis, and GMP-grade APIs. Creates synergies with Bioserve's existing oligosynthesis operations.
- Steminent Biotherapeutics Inc.strategicREPROCELL holds exclusive commercialization license for Stemchymal® (stem cell therapy) in Japan for treatment of Spinocerebellar Ataxia (SCA). Phase II clinical trial results announced April 2025 showing positive outcomes.
- Qkine Ltd.coreGlobal distributorship partnership for high-quality bioactive proteins including growth factors and cytokines for stem cell culture. Qkine's animal-origin-free manufacturing combined with REPROCELL's stem cell expertise and global network enables distribution to stem cell scientists worldwide.
- REPROCELL Inc.coreParent company and strategic partner. Bioserve is the India operations of Japan's first iPSC company. REPROCELL provides access to StemRNA™ technology, global product portfolio, and operates subsidiaries in Americas (REPROCELL USA) and Europe (REPROCELL Europe).
- Axion BiosystemsminorGlobal product partner for research products distributed through Bioserve in India
- Glen ResearchminorGlobal product partner for oligonucleotide synthesis reagents and products distributed through Bioserve in India
Scale indicators3 records
Recent moves6 records
Expansion highlights6 records
Bioserve competitors and assessment
Company assessmentDirect peers
- MedGenome: India-based genomics and clinical diagnostics company offering NGS-based oncology panels, hereditary cancer testing, and molecular diagnostics — directly comparable to Bioserve's PreciONC oncology and clinical diagnostics services.
- Strand Life Sciences: India-based clinical genomics and bioinformatics company providing cancer panel testing, hereditary cancer diagnostics, and molecular services to hospitals and pharma — directly overlapping with Bioserve's clinical diagnostics and molecular services portfolio.
- SciGenom Labs: India-based genomics services company offering NGS, Sanger sequencing, and molecular biology services to research and pharma customers — directly overlapping with Bioserve's molecular services offering within India.
- Ocimum Biosolutions: India-based genomics and bioinformatics CRO providing microarray, NGS, gene expression, and bioIT services to global pharma and research customers — overlapping with Bioserve's molecular biology and bioinformatics service lines.
Broad incumbents
- Integrated DNA Technologies (IDT): Global market leader in custom oligonucleotide synthesis (now part of Danaher) with industry-leading product depth, NGS oligos, and molecular tools — the dominant incumbent competitor to Bioserve's core oligo synthesis business.
- GenScript: Global CRO/CDMO with extensive custom oligonucleotide synthesis, gene synthesis, peptide synthesis, and protein services. A major incumbent serving Indian pharma and academic customers with broader catalog and global scale than Bioserve.
- Eurofins Genomics: Global genomics services provider offering custom oligos, Sanger and NGS sequencing, and genotyping — directly competing with Bioserve's molecular services and oligo synthesis but with much broader geographic and catalog reach.
Regional players
- Macrogen: Korea-based genomics services company providing Sanger sequencing, NGS, and oligo synthesis across Asia. Comparable service menu to Bioserve but serves Asian customers from Korean operations rather than India.
- Bioneer: Korea-based molecular biology company offering oligonucleotide synthesis, NGS services, and molecular diagnostics — comparable in service menu to Bioserve and connected via the HLB PEP/Asian biotech distribution ecosystem.
Emerging players
- 4baseCare: India-based precision oncology company offering NGS-based cancer panels and molecular diagnostics — emerging competitor in the same Indian clinical genomics market as Bioserve's PreciONC oncology suite.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Bioserve social profiles
Digital presenceBioserve compliance and trust
Trust signalCompliance2 records
Bioserve financial estimates
Financial estimateRevenue estimate
Valuation estimate
Bioserve leadership team
Management profileNumber of profiles
Profiles4 records
Bioserve funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Bioserve M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Bioserve
What does Bioserve do?
Bioserve is a molecular biology services and genomics company offering custom oligonucleotide synthesis (DNA oligos up to 150 bases), clinical diagnostics for oncology (BRCA, MSI, comprehensive cancer panels, lung RNA fusion panels), molecular services (Sanger sequencing, NGS, DNA barcoding, microbial identification, cell line authentication), neoantigen discovery for cancer immunotherapy, and stem cell research products including iPSCs, MSCs, growth factors, cytokines, and 3D cell culture systems. The company distributes REPROCELL group products, HLB PEP peptides, and Qkine growth factors to pharmaceutical, academic, and clinical customers in India.
Is Bioserve a public or private company?
Bioserve is a private company. It is classified as corporate owned and is currently operating.
When was Bioserve founded?
Bioserve was founded in 1994. It employs 51 to 100 people.
Where is Bioserve based?
Bioserve is headquartered in Hyderabad, India, in the Asia region.
How does Bioserve make money?
Five revenue lines are on record. Oligonucleotide Synthesis Services are the primary driver. The others are peptide Synthesis Services, clinical Diagnostics Services, molecular Services and stem Cell Products.
Who are Bioserve's main competitors?
Direct peers on record are MedGenome, Strand Life Sciences, SciGenom Labs and Ocimum Biosolutions. Broad incumbents are Integrated DNA Technologies (IDT), GenScript and Eurofins Genomics. Regional players are Macrogen and Bioneer. 4baseCare is listed as an emerging player.
Does Bioserve have an API?
No public API is recorded for Bioserve.
What industry is Bioserve in?
Bioserve's product category is Genomics & Molecular Biology Services. Its primary akta.pro industry code is HLAGAGAC, mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA), with a secondary code of HLAGAEAB, Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry). Its NAICS code is 621511 and its SIC code is 8071.